Announcement PDF Atomo Diagnostics Limited ACN 142 925 684 Level 1, 3-5 George St Leichhardt NSW 2040 ASX Announcement 15 January 2026 Atomo Secures a Significant Order for HIV Self-Test SYDNEY, Australia, 15 January 2026 - Atomo Diagnostics Limited (ASX:AT1) (Atomo) is pleased to announce securing a purchase order for $502,000 worth of HIV Self-Tests for supply to an African country. Manufactured by Atomo under the Mylan brand and paid for with funding from the Global Fund, the order is planned for supply in March. Atomo considers the revenue from this order to be material. Atomo’s Managing Director John Kelly said “we are delighted to see continued demand for our HIV Self-Test in Africa, where it remains critical that people at risk of HIV retain access to good quality, reliable HIV tests that can be performed easily and discreetly.” For more information, please contact: John Kelly Atomo Diagnostics john.kelly@atomodiagnostics.com Phone: +61 401 922 279 This announcement was authorised by the Managing Director & CEO. About Atomo Atomo is an Australian headquartered medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market. Atomo’s unique patented devices simplify testing procedures, enhance usability and improve reliability across rapid point-of-care (POC) and at-home testing applications. The Company has successfully commercialised a number of products across international markets and has supply agreements in place for testing applications targeting infectious diseases including HIV, viral vs bacterial differentiation and the early detection of pregnancy. See more at www.atomodiagnostics.com